Biotech | April 25, 2022
Shilpa Medicare receives NoC for biosimilar Aflibercept
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
It plans to deliver over 300 million doses to the Indian government
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
This is the first of its kind vaccine for Covid 19 to get the go-ahead
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
CDSCO to fast-track trials and approval for COVID19 vaccine
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
Subscribe To Our Newsletter & Stay Updated
